217 related articles for article (PubMed ID: 17941458)
1. [Apomorphine in off state--clinical experience].
Rudzińska M; Szczudlik A
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
3. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
4. Apomorphine hydrochloride for the treatment of Parkinson's disease.
Unti E; Ceravolo R; Bonuccelli U
Expert Rev Neurother; 2015; 15(7):723-32. PubMed ID: 26037961
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine in the treatment of Parkinson's disease.
Hagell P; Odin P
J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
[TBL] [Abstract][Full Text] [Related]
6. [Apomorphine in the treatment of Parkinson's Disease].
Dressler D
Nervenarzt; 2005 Jun; 76(6):681-9. PubMed ID: 15592807
[TBL] [Abstract][Full Text] [Related]
7. [Apomorphine in treatment of Parkinson's disease with fluctuations].
Zaleska B; Domzał T
Neurol Neurochir Pol; 1999; 33(6):1297-303. PubMed ID: 10791032
[TBL] [Abstract][Full Text] [Related]
8. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
9. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
Manson AJ; Turner K; Lees AJ
Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
[TBL] [Abstract][Full Text] [Related]
10. Apomorphine - pharmacological properties and clinical trials in Parkinson's disease.
Jenner P; Katzenschlager R
Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S13-S21. PubMed ID: 27979722
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
12. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
13. Apomorphine: an underutilized therapy for Parkinson's disease.
Poewe W; Wenning GK
Mov Disord; 2000 Sep; 15(5):789-94. PubMed ID: 11009181
[TBL] [Abstract][Full Text] [Related]
14. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
15. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.
Colzi A; Turner K; Lees AJ
J Neurol Neurosurg Psychiatry; 1998 May; 64(5):573-6. PubMed ID: 9598668
[TBL] [Abstract][Full Text] [Related]
16. Clinical insights into use of apomorphine in Parkinson's disease: tools for clinicians.
Henriksen T
Neurodegener Dis Manag; 2014; 4(3):271-82. PubMed ID: 25095821
[TBL] [Abstract][Full Text] [Related]
17. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
18. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
Obering CD; Chen JJ; Swope DM
Pharmacotherapy; 2006 Jun; 26(6):840-52. PubMed ID: 16716137
[TBL] [Abstract][Full Text] [Related]
19. [Apomorphine: an alternative in the control of motor fluctuations in Parkinson's disease].
Ferraz HB; Azevedo-Silva SM; Borges V; Rocha MS; Andrade LA
Arq Neuropsiquiatr; 1995 Jun; 53(2):245-51. PubMed ID: 7487531
[TBL] [Abstract][Full Text] [Related]
20. [Proposed alternative to standard apomorphine challenge test].
Martínez-Castrillo JC; Burguera JA
Rev Neurol; 2012; 55 Suppl 1():S11-3. PubMed ID: 23169227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]